Should I Buy QNTM? QNTM 2026 Analysis

Should You Buy Quantum Biopharma Ltd (QNTM) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

4.870

1 Day change

-0.81%

52 Week Range

38.250

Analysis Updated At

2026/01/26

Quantum Biopharma Ltd (QNTM) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows weak financial performance, negative technical indicators, and lacks positive catalysts. Additionally, the ongoing class action lawsuits and allegations of stock manipulation present significant risks to shareholder confidence and the stock's future performance.

Technical Analysis

The MACD histogram is negative and expanding downward (-0.0343), indicating bearish momentum. The RSI (26.278) is in the neutral zone but close to oversold territory. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading below key support levels (S1: 6.216, S2: 5.865), suggesting further downside potential.

Options Data

Positive Catalysts

NULL identified.

Neutral/Negative Catalysts

Class action lawsuit alleging securities fraud by the company and its executives.
Allegations of stock price manipulation by major financial institutions, which could further erode investor confidence.

Financial Performance

In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of -$5,319,029 (up 32.47% YoY), and a significant EPS decline (-67.96% YoY to -1.4). Gross margin remained at 0%. Overall, the financials indicate poor performance with no signs of growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes available.

Analyst Rating

Wall Street analysts forecast QNTM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QNTM is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold